Recent Updates
Recently added Catalysts
PHAR Positive Sentiment

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Thursday, April 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pharming Group N.V. has announced the filing of its Annual Report for the year ending December 31, 2025, which is now available online. Additionally, the company has filed its Annual Report on Form 20-F with the U.S. SEC. Pharming is committed to developing innovative treatments for patients with rare diseases.
Price reaction · baseline $16.92 (2026-04-01 close) · hit pre-market · 1 other PHAR headline(s) in the window, move may be shared
day 0 close · peak
-1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pharming has successfully filed its Annual Report for 2025.
  • The report is accessible to investors and the public.
  • Pharming continues to focus on innovative medicines for rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
9.3%
average across 4 past catalysts
Lead asset
Recombinant human C1 inhibitor
Phase 3 · Hereditary Angioedema

Full Press Release Details

Leiden, the Netherlands, April 2, 2026:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available atannualreport.pharming.comand under Investors/Financial documents on the Pharming.com website.
The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report on Form 20-F can be found under Investors/SEC filings on Pharming.com and through the SEC website once it has been filed.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
For more information, visitwww.pharming.comand find us onLinkedIn.
For further public information, contact:Investor RelationsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696E:investor@pharming.com

Frequently Asked Questions

Where can I find Pharming's 2025 Annual Report?

Pharming's 2025 Annual Report is available at annualreport.pharming.com.

What is Form 20-F?

Form 20-F is a filing required by the SEC for foreign companies, detailing financial performance.

What does Pharming specialize in?

Pharming specializes in developing treatments for rare, debilitating, and life-threatening diseases.

Who can I contact for investor relations at Pharming?

You can contact Michael Levitan, VP Investor Relations, at investor@pharming.com.

ShareAdd on Google
Tags: PHAR Viatris Investor Conferences Healthcare Pharming 2025 Annual Report Form 20-F biopharmaceuticals rare diseases
Last updated: Apr 2, 2026

Biotech snapshot

Lead asset
Recombinant human C1 inhibitorPhase 3
Hereditary Angioedema →

Catalyst track record

+36%
best trade around PHAR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PHAR.

See every catalyst's timing & PoA →